DMAC — DiaMedica Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401040 ·
Last close
$6.52
Market Cap
$351.60M
52W High
$8.52
52W Low
$5.24
ADV30
156,679
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,482,000 | -10,042,000 | 53,080,000 | 4,868,000 | 5,845,000 |
| Dec 2025 | 0 | — | -9,213,000 | -8,740,000 | 61,371,000 | 15,647,000 | 5,260,000 |
| Sep 2025 | 0 | — | -9,033,000 | -8,620,000 | 57,047,000 | 3,326,000 | 5,425,000 |
| Jun 2025 | 0 | — | -8,007,000 | -7,699,000 | 31,470,000 | 4,109,000 | 4,300,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-30,995,000
Investing CF
$-10,928,000
Financing CF
$44,202,000
CapEx
$-36,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.72
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-182,810,000
Inventory
—
Receivables
$301,000
ST Investments
$46,463,000
EBIT TTM
$-36,735,000
Pretax Income TTM
$-35,072,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,397,000 | -32,766,000 | 61,371,000 | 5,260,000 | — | -29,062,000 |
| Dec 2024 | 0 | -26,681,000 | -24,444,000 | 46,345,000 | 5,627,000 | — | -22,076,000 |
| Dec 2023 | 0 | -21,267,000 | -19,381,000 | 54,160,000 | 3,103,000 | — | -18,728,000 |
| Dec 2022 | 0 | -14,001,000 | -13,676,000 | 34,395,000 | 2,568,000 | — | -11,511,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.81
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $6.69 · call volume: 17 · put volume: 11Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | $355.97M | $3.76 | — |
| ABEO | ABEONA THERAPEUTICS INC. | $346.54M | $6.06 | — |
| PRQR | ProQR Therapeutics N.V. | $342.92M | $2.43 | — |
| LYEL | Lyell Immunopharma, Inc. | $361.21M | $14.74 | — |
| UPB | Upstream Bio, Inc. | $362.04M | $6.61 | — |
News headlines (Yahoo Finance, 1h cache)
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
2026-08-18 01:29 · Yahoo
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
2026-08-13 16:00 · Yahoo
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...
2026-08-11 19:01 · Yahoo
DiaMedica Therapeutics Q2 Earnings Call Highlights
2026-08-11 13:04 · Yahoo
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential
2026-08-03 15:09 · Yahoo
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17 20:30 · Yahoo
DiaMedica Therapeutics Q1 Earnings Call Highlights
2026-05-07 17:42 · Yahoo
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
2026-06-23 12:30 · Yahoo
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
2026-06-16 12:30 · Yahoo
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary
2026-08-11 17:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.